Royal Bank Of Canada Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Posted by Stanley Muller on Jul 7th, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by research analysts at Royal Bank Of Canada from $707.00 to $696.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 4.07% from the stock’s current price.

REGN has been the subject of several other research reports. HSBC reduced their target price on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a report on Tuesday. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Finally, Cantor Fitzgerald dropped their target price on shares of Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $790.46.

View Our Latest Analysis on REGN

Regeneron Pharmaceuticals Stock Up 2.9%

Shares of NASDAQ:REGN traded up $19.00 during mid-day trading on Tuesday, hitting $668.80. 205,279 shares of the company traded hands, compared to its average volume of 867,025. The stock has a 50-day moving average price of $652.48 and a two-hundred day moving average price of $725.31. Regeneron Pharmaceuticals has a 12-month low of $537.45 and a 12-month high of $821.11. The stock has a market cap of $70.71 billion, a P/E ratio of 16.29, a P/E/G ratio of 1.44 and a beta of 0.24. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the firm posted $8.22 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 37.44 earnings per share for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Nordea Investment Management AB raised its stake in shares of Regeneron Pharmaceuticals by 118.1% during the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after acquiring an additional 74,350 shares in the last quarter. Lockheed Martin Investment Management Co. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $2,702,000. Mackenzie Financial Corp boosted its stake in shares of Regeneron Pharmaceuticals by 26.8% in the 3rd quarter. Mackenzie Financial Corp now owns 128,623 shares of the biopharmaceutical company’s stock valued at $72,321,000 after purchasing an additional 27,205 shares in the last quarter. Asio Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $3,422,000. Finally, Robeco Institutional Asset Management B.V. grew its holdings in shares of Regeneron Pharmaceuticals by 116.6% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock valued at $202,114,000 after purchasing an additional 140,966 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.